Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents

• US 8,247,420 B2
• Filed: 05/21/2008
• Issued: 08/21/2012
• Est. Priority Date: 05/21/2007
• Status: Active Grant

• Current Assignee: Reviva Pharmaceuticals, Inc.
• Original Assignee: Reviva Pharmaceuticals, Inc.
• Inventors: Bhat, Laxminarayan, Mohapatra, Prabhu P., Bhat, Seema Rani
• Primary Examiner(s): Wilson, James O
• Assistant Examiner(s): Sackey, Ebenezer O
• Application Number:
  US12/124,985
• Publication Number:
  US 20080293736A1
• Time in Patent Office: 1,553 Days
• Field of Search: 514/253.04, 544/363
• US Class Current: 514/253.04
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: C07D 215/22 attached in position 2 or 4
• CPC Class Codes: C07D 215/48 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The present invention provides novel quinolinone derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression.

Claims

1. A compound having structural Formula (II):

2. The compound of claim 1, wherein the spacer is aryloxyalkyl.

3. The compound of claim 2, wherein the spacer is alky or substituted alkyl.

8. The compound of claim 1 having structural Formula (VII):

12. The compound of claim 1, wherein X is O.

13. The compound of claim 1, wherein X is NH.

14. The compound of claim 1, wherein the spacer is aryloxyalkyl.

15. The compound of claim 1, wherein R²-R⁶ are hydrogen, and R⁷ is alkyl.

16. The compound of claim 1, which is Compound 8,

17. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle.

18. A method of treating a disease in a patient, the method comprising:

administering to a patient in need thereof the pharmaceutical composition of claim 17, wherein the disease is schizophrenia, acute manic, bipolar disorder, or depression.

19. The method of claim 18, wherein the administering is oral, mucosal, rectal, parenteral, transdermal, or subcutaneous administration.

20. The method of claim 18, wherein the disease is schizophrenia.

21. The method of claim 18, wherein the disease is bipolar disorder.

22. The method of claim 18, wherein the disease is depression.

23. The method of claim 18, wherein the disease is acute manic.

4. A compound having structural Formula (III):

9. The compound of claim 4 having structural Formula (VIII):

5. A compound having structural Formula (IV):

6. A compound having structural Formula (V):

10. The compound of claim 6 having structural Formula (IX):

7. A compound having structural Formula (VI):

11. The compound of claim 7 having structural Formula (X):